European Commission Approves BioMarin's VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close

Achondroplasia is the Most Common Cause of Dwarfism

close

Get every new post delivered right to your inbox.

Original Source